Edition:
United Kingdom

Alder Biopharmaceuticals Inc (ALDR.OQ)

ALDR.OQ on NASDAQ Stock Exchange Global Market

16.90USD
25 Sep 2018
Change (% chg)

-- (--)
Prev Close
$16.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
199,907
52-wk High
$20.85
52-wk Low
$9.60

Chart for

About

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated... (more)

Overall

Beta: 2.62
Market Cap(Mil.): $863.35
Shares Outstanding(Mil.): 67.71
Dividend: --
Yield (%): --

Financials

  ALDR.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -5.14 -- --
ROI: -76.39 1.79 14.61
ROE: -76.45 3.28 16.33

BRIEF-Alder Biopharmaceuticals Reports Q1 Loss Per Share Of $1.73

* ALDER BIOPHARMACEUTICALS® REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS

08 May 2018

BRIEF-Alder Biopharmaceuticals Appoints Jeremy Green To Its Board Of Directors

* ALDER BIOPHARMACEUTICALS APPOINTS JEREMY GREEN TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

26 Apr 2018

BRIEF-Alder Biopharmaceuticals - New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals In Patients With Episodic Migraine

* ALDER BIOPHARMACEUTICALS® NEW DATA DEMONSTRATED EPTINEZUMAB INCREASED MIGRAINE-FREE INTERVALS (UP TO 32.5 DAYS) AND IMPROVED QUALITY-OF-LIFE OUTCOMES IN PATIENTS WITH EPISODIC MIGRAINE

25 Apr 2018

BRIEF-Alder Biopharmaceuticals Presents New 12-Month Data Of Eptinezumab In Promise 1 Phase 3 Trial

* ALDER BIOPHARMACEUTICALS® PRESENTS NEW 12-MONTH DATA OF EPTINEZUMAB IN PROMISE 1 PHASE 3 TRIAL SHOWING LONG-TERM REDUCTION IN EPISODIC MIGRAINE

24 Apr 2018

BRIEF-Alder Biopharmaceuticals Inc To Present New Phase 3 Migraine Prevention Data For Eptinezumab

* ALDER BIOPHARMACEUTICALS INC - TO PRESENT NEW PHASE 3 MIGRAINE PREVENTION DATA FOR EPTINEZUMAB AT 70TH ANNUAL AMERICAN ACADEMY OF NEUROLOGY MEETING Source text for Eikon: Further company coverage:

18 Apr 2018

BRIEF-Alder Biopharmaceuticals Appoints Erin Lavelle To Newly Created Role Of Chief Operating Officer

* ALDER BIOPHARMACEUTICALS® APPOINTS ERIN LAVELLE TO NEWLY CREATED ROLE OF CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage:

16 Apr 2018

Competitors

Earnings vs. Estimates